The present invention relates to a double-stranded oligonucleotide capable of inhibiting CTGF expression with a very specific and high efficiency, a double-stranded oligonucleotide structure and nanoparticles comprising the double-stranded oligonucleotide, and a use thereof in preventing or treating of fibrotic or respiratory diseases.

The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.

A compound represented by the formula (I):

##STR00001##

wherein each symbol is as described in the description, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

The present invention relates to a prophylactic and/or therapeutic agent for cancer containing an mPGES-1 inhibitor as an active ingredient, the agent being useful in combination with an immune checkpoint inhibitor, and the invention has industrial applicability.

The present specification provides an antisense oligomer capable of causing simultaneous skipping of a plurality of exons in pre-mRNA of interest, and a pharmaceutical composition comprising the oligomer. The present specification also provides an antisense oligomer or a pharmaceutically acceptable salt thereof, or hydrate thereof which causes simultaneous skipping of two or more numerically consecutive exons from pre-mRNA of interest, the antisense oligomer comprising a base sequence complementary to a base sequence of a region including the vicinity of a donor of any intron in the pre-mRNA of interest, or a region including the vicinity of an acceptor of any intron in the pre-mRNA of interest, or a partial base sequence thereof.

The present disclosure provides a composition, a combination product, a medical device and the like for treating or preventing cancer or a tumor or preventing the recurrence of the cancer or the tumor. The present disclosure provides a composition, a combination product and a medical device for treating or preventing cancer or a tumor or preventing the recurrence of the cancer or the tumor, each of which comprises an immune checkpoint inhibitor and a dendritic cell direct activator or means. In another aspect, the present disclosure provides: a novel cancer treatment method which comprises carrying out a treatment of cancer by employing a combination of a treatment by the administration of an immune checkpoint inhibitor and a treatment for improving the sensitivity to the immune checkpoint inhibitor and, therefore, can be used as an immunotherapy that can be expected to have an excellent therapeutic effect; and a medicine which can be used for the cancer treatment method.

The present invention aims to provide a highly safe composition that can be used for improving or maintaining mitochondrial function and/or mitochondrial energy production capacity or reducing a decline in mitochondrial function and/or mitochondrial energy production capacity and that allows easy intake and continuous ingestion without risk of side effects. The present invention also aims to provide, for example a method of improving or maintaining mitochondrial function and/or mitochondrial energy production capacity or reducing a decline in mitochondrial function and/or mitochondrial energy production capacity. The present invention relates to, for example, a composition containing at least one sesamin-class compound and pyrroloquinoline quinone (PQQ) or a salt thereof.

The present invention aims to provide a highly safe composition that can be used for improving or maintaining mitochondrial function and/or mitochondrial energy production capacity or reducing a decline in mitochondrial function and/or mitochondrial energy production capacity and that allows easy intake and continuous ingestion without risk of side effects. The present invention also aims to provide, for example a method of improving or maintaining mitochondrial function and/or mitochondrial energy production capacity or reducing a decline in mitochondrial function and/or mitochondrial energy production capacity. The present invention relates to, for example, a composition containing at least one sesamin-class compound and pyrroloquinoline quinone (PQQ) or a salt thereof.

The present disclosure addresses the problem of providing at least a composition for suppressing obesity and the problem is solved by a composition for suppressing obesity comprising a prenylflavonoid represented by general formula (1), as an active ingredient, below.

This disclosure provides pharmaceutical compositions comprising amino acid entities and uses thereof. Methods for treating post-acute sequelae of COVID-19 comprising administering an effective amount of the compositions to a subject in need thereof are also disclosed.

Disclosed are: a method for activating a helper T cell, which comprises the step of adding a WT1 peptide to an antigen-presenting cell to activate the helper T cell, wherein the WT1 peptide is capable of binding to any one selected from an HLA-DRB1*1501 molecule, an HLA-DPB1*0901 molecule and an HLA-DPB1*0501 molecule; a composition for use in the method; a therapeutic and/or prophylactic method for cancer by activating a helper T cell; a pharmaceutical composition for use in the therapeutic and/or prophylactic method; and others.